We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+21.26%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.97B
AUM Growth
+$710M
Cap. Flow
+$33.6M
Cap. Flow %
0.68%
Top 10 Hldgs %
43.85%
Holding
701
New
35
Increased
130
Reduced
246
Closed
41

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$31M
2
BTI icon
British American Tobacco
BTI
+$29.2M
3
SAP icon
SAP
SAP
+$27.1M
4
HOOD icon
Robinhood
HOOD
+$17.9M
5
CLS icon
Celestica
CLS
+$13.7M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$29.1M
2
TSM icon
TSMC
TSM
+$26.3M
3
META icon
Meta Platforms (Facebook)
META
+$23.5M
4
BEKE icon
KE Holdings
BEKE
+$22.1M
5
TCOM icon
Trip.com Group
TCOM
+$17M

Sector Composition

Rank Sector Weight
1 Technology 46.19%
2 Consumer Discretionary 14.25%
3 Communication Services 13.85%
4 Healthcare 7.17%
5 Consumer Staples 6.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
626
DELISTED
Esperion Therapeutics
ESPR
$4.97K ﹤0.01%
5,045
– –
CDXS icon
627
Codexis
CDXS
$136M
$4.93K ﹤0.01%
2,019
– –
DSGN icon
628
Design Therapeutics
DSGN
$741M
$4.88K ﹤0.01%
1,449
– –
SLDB icon
629
Solid Biosciences
SLDB
$785M
$4.83K ﹤0.01%
991
– –
SCPH
630
DELISTED
scPharmaceuticals
SCPH
$4.73K ﹤0.01%
1,242
– –
CRGX
631
DELISTED
CARGO Therapeutics
CRGX
$4.71K ﹤0.01%
1,142
– –
EDIT icon
632
Editas Medicine
EDIT
$402M
$4.65K ﹤0.01%
2,113
– –
LRMR icon
633
Larimar Therapeutics
LRMR
$398M
$4.58K ﹤0.01%
1,583
– –
OMER icon
634
Omeros
OMER
$816M
$4.45K ﹤0.01%
1,483
– –
FDMT icon
635
4D Molecular Therapeutics
FDMT
$515M
$4.25K ﹤0.01%
1,147
– –
VYGR icon
636
Voyager Therapeutics
VYGR
$184M
$4.21K ﹤0.01%
1,355
– –
ENTA icon
637
Enanta Pharmaceuticals
ENTA
$367M
$3.97K ﹤0.01%
525
– –
CMPS
638
Compass Pathways
CMPS
$1.46B
$3.53K ﹤0.01%
1,261
– –
ALEC icon
639
Alector
ALEC
$169M
$3.4K ﹤0.01%
2,429
– –
LXEO icon
640
Lexeo Therapeutics
LXEO
$345M
$3.3K ﹤0.01%
820
– –
KYTX icon
641
Kyverna Therapeutics
KYTX
$455M
$3.29K ﹤0.01%
1,070
– –
FATE icon
642
Fate Therapeutics
FATE
$270M
$3.06K ﹤0.01%
2,737
– –
NKTX icon
643
Nkarta
NKTX
$159M
$2.91K ﹤0.01%
1,751
– –
IRWD icon
644
Ironwood Pharmaceuticals
IRWD
$626M
$2.85K ﹤0.01%
3,971
– –
NMRA icon
645
Neumora Therapeutics
NMRA
$311M
$2.85K ﹤0.01%
3,883
– –
CCCC icon
646
C4 Therapeutics
CCCC
$393M
$2.5K ﹤0.01%
1,751
– –
CLYM
647
Climb Bio
CLYM
$704M
$2K ﹤0.01%
1,616
– –
MGNX icon
648
MacroGenics
MGNX
$245M
$1.88K ﹤0.01%
1,557
– –
TCRX icon
649
TScan Therapeutics
TCRX
$50.6M
$1.77K ﹤0.01%
1,218
– –
PLRX icon
650
Pliant Therapeutics
PLRX
$66.3M
$1.75K ﹤0.01%
1,509
– –
24 25
26
27 28

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.03B AUM 40.55% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return

GF Fund Management's Q2 2025 Portfolio in Review

As of Q2 2025, GF Fund Management held 701 positions worth $4.97B, up 17% from $4.26B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

GF Fund Management's Q2 2025 filing shows 35 new, 130 increased, 246 reduced and 41 closed positions. Its largest new stake was Shopify: 120,000 shares worth $13.8M. The largest sale was NVIDIA, an estimated $29.1M.

By sector, the portfolio is most concentrated in Technology at 46% of assets, up from 42% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • GF Fund Management's largest Q2 2025 buy was Shopify: 120,000 shares worth $13.8M.
  • GF Fund Management added most to UnitedHealth in Q2 2025, an estimated $31M increase.
  • GF Fund Management's biggest Q2 2025 reduction was NVIDIA, cutting an estimated $29.1M.
  • GF Fund Management fully exited Salesforce in Q2 2025, selling an estimated $9.77M.
  • GF Fund Management's ten largest holdings make up 44% of its $4.97B portfolio in Q2 2025.
  • GF Fund Management opened 35 new positions and closed 41 in Q2 2025.
  • GF Fund Management's portfolio value rose 17% quarter-over-quarter to $4.97B.

Based on GF Fund Management's 13F filing for Q2 2025, filed 22 Jul 2025.